David B. Konrad

Ludwig-Maximilians-Universität München
Country flagGermany

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Mutation-selective drugs constitute a great advancement in personalized anticancer treatment with increased quality of life and overall survival in cancers. However, the high adaptability and evasiveness of cancers can lead to disease progression and the development of drug resistance, which cause recurrence and metastasis. A common characteristic in advanced neoplastic cancers is the epithelial-mesenchymal transition (EMT) which is strongly interconnected with H 2 O 2 signaling, increased motility and invasiveness. H 2 O 2 relays its signal through the installation of oxidative posttranslational modifications on cysteines. The increased H 2 O 2 levels that are associated with an EMT confer a heightened sensitivity towards the induction of ferroptosis as a recently discovered vulnerability.

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Axel Imhof

Professor for Proteinanalytics

Ludwig-Maximilians-Universität München Medizinische Fakultät

GERMANY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.